DE69528591D1 - PRODUCTION OF THE INHIBITOR FOR THE COMPLEX FORMATION OF THE TISSUE FACTOR - Google Patents

PRODUCTION OF THE INHIBITOR FOR THE COMPLEX FORMATION OF THE TISSUE FACTOR

Info

Publication number
DE69528591D1
DE69528591D1 DE69528591T DE69528591T DE69528591D1 DE 69528591 D1 DE69528591 D1 DE 69528591D1 DE 69528591 T DE69528591 T DE 69528591T DE 69528591 T DE69528591 T DE 69528591T DE 69528591 D1 DE69528591 D1 DE 69528591D1
Authority
DE
Germany
Prior art keywords
tissue factor
production
inhibitor
complex formation
tfpi
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69528591T
Other languages
German (de)
Other versions
DE69528591T2 (en
Inventor
A Innis
A Creasey
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Vaccines and Diagnostics Inc
Original Assignee
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Corp filed Critical Chiron Corp
Application granted granted Critical
Publication of DE69528591D1 publication Critical patent/DE69528591D1/en
Publication of DE69528591T2 publication Critical patent/DE69528591T2/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8114—Kunitz type inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

A method for the production of Tissue Factor Pathway Inhibitor (TFPI) and Tissue Factor Pathway Inhibitor 2 (TFPI-2), and muteins thereof is disclosed wherein the protein is retained within a yeast cell during growth of the yeast cell and recovered from an insoluble fraction prepared from yeast cells containing the protein.
DE69528591T 1994-08-05 1995-07-25 PRODUCTION OF THE INHIBITOR FOR THE COMPLEX FORMATION OF THE TISSUE FACTOR Expired - Fee Related DE69528591T2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28653094A 1994-08-05 1994-08-05
PCT/US1995/009377 WO1996004377A1 (en) 1994-08-05 1995-07-25 Production of tissue factor pathway inhibitor

Publications (2)

Publication Number Publication Date
DE69528591D1 true DE69528591D1 (en) 2002-12-05
DE69528591T2 DE69528591T2 (en) 2003-02-20

Family

ID=23099037

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69528591T Expired - Fee Related DE69528591T2 (en) 1994-08-05 1995-07-25 PRODUCTION OF THE INHIBITOR FOR THE COMPLEX FORMATION OF THE TISSUE FACTOR

Country Status (8)

Country Link
US (2) US6103500A (en)
EP (1) EP0774001B1 (en)
JP (2) JP3779728B2 (en)
AT (1) ATE226249T1 (en)
AU (1) AU707762B2 (en)
CA (1) CA2196296C (en)
DE (1) DE69528591T2 (en)
WO (1) WO1996004377A1 (en)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6057287A (en) 1994-01-11 2000-05-02 Dyax Corp. Kallikrein-binding "Kunitz domain" proteins and analogues thereof
DE69528591T2 (en) * 1994-08-05 2003-02-20 Chiron Corp PRODUCTION OF THE INHIBITOR FOR THE COMPLEX FORMATION OF THE TISSUE FACTOR
US5866543A (en) * 1995-06-05 1999-02-02 Corvas International, Inc. Nematode-extracted anticoagulant protein
US5863894A (en) * 1995-06-05 1999-01-26 Corvas International, Inc. Nematode-extracted anticoagulant protein
US5945275A (en) * 1994-10-18 1999-08-31 Corvas International, Inc. Nematode-extracted anticoagulant protein
US5866542A (en) * 1994-10-18 1999-02-02 Corvas International, Inc. Nematode-extracted anticoagulant protein
CA2202351A1 (en) * 1994-10-18 1996-04-25 George Phillip Vlasuk Nematode-extracted serine protease inhibitors and anticoagulant proteins
US5872098A (en) * 1995-06-05 1999-02-16 Corvas International, Inc. Nematode-extracted anticoagulant protein
JP3811186B2 (en) 1994-10-18 2006-08-16 コーバス インターナショナル， インコーポレイテッド Serine protease inhibitors and anticoagulant proteins extracted from nematodes
ES2248818T3 (en) * 1995-06-07 2006-03-16 Chiron Corporation METHOD OF SOLUBILIZATION, PURIFICATION AND REPLEGATION OF PROTEINS.
EP0791358B1 (en) * 1995-08-09 2002-01-16 Toray Industries, Inc. Therapeutic agent for ophthalmic diseases
EP1000161B1 (en) 1997-03-26 2006-02-22 Imperial College Innovations Limited Anticoagulant fusion protein anchored to cell membrane
PT2311432E (en) 2002-06-07 2015-02-09 Dyax Corp Modified kunitz domain polypeptides and their use for reducing ischemia or the onset of a systemic inflammatory response associated with a surgical procedure
US7153829B2 (en) 2002-06-07 2006-12-26 Dyax Corp. Kallikrein-inhibitor therapies
PT1599222E (en) * 2003-01-08 2009-06-12 Novartis Vaccines & Diagnostic Stabilized aqueous compositions comprising tissue factor pathway inhibitor (tfpi) or tissue factor pathway inhibitor variant
EP1660661A2 (en) * 2003-08-08 2006-05-31 Arriva Pharmaceuticals, Inc. Methods of protein production in yeast
CA2535562A1 (en) * 2003-08-13 2005-03-03 Chiron Corporation Improved method of purifying tfpi and tfpi analogs
WO2005048985A2 (en) * 2003-11-14 2005-06-02 Baxter International Inc. Alpha 1-antitrypsin compositions and treatment methods using such compositions
US7235530B2 (en) 2004-09-27 2007-06-26 Dyax Corporation Kallikrein inhibitors and anti-thrombolytic agents and uses thereof
JP2008515908A (en) * 2004-10-06 2008-05-15 ユニバーシティー オブ ロチェスター Treatment of pulmonary hypertension using drugs that inhibit the tissue factor pathway
WO2007070372A2 (en) * 2005-12-09 2007-06-21 Entremed, Inc. Compositions and methods for inhibiting cellular proliferation
SI1981519T1 (en) 2005-12-29 2018-05-31 Dyax Corp. Protease inhibition
CN100451116C (en) * 2006-09-14 2009-01-14 中国医学科学院生物医学工程研究所 Human tissue factor pathway inhibitory factor mutation gene mTFPI, recombination carrier including the same and host cell thereof
WO2009026334A2 (en) * 2007-08-21 2009-02-26 Genzyme Corporation Treatment with kallikrein inhibitors
AU2010203712A1 (en) * 2009-01-06 2010-07-15 Dyax Corp. Treatment of mucositis with kallikrein inhibitors
US8088599B2 (en) * 2009-02-06 2012-01-03 Fudan University Nucleic acids encoding genetically modified tissue factor pathway inhibitor (TFPI) and method of making the same
LT2521568T (en) * 2010-01-06 2018-12-10 Dyax Corp. Plasma kallikrein binding proteins
CN105713092B (en) 2011-01-06 2019-09-10 戴埃克斯有限公司 Blood plasma prekallikrein binding protein
KR102555955B1 (en) 2014-03-27 2023-07-18 다케다 파머수티컬 컴패니 리미티드 Compositions and methods for treatment of diabetic macular edema
AU2016366557B2 (en) 2015-12-11 2024-01-25 Takeda Pharmaceutical Company Limited Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4751180A (en) * 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
US5106833A (en) * 1987-07-23 1992-04-21 Washington University Coagulation inhibitors
US4966852A (en) * 1987-07-23 1990-10-30 Monsanto Company DNA clone of human tissue factor inhibitor
DK408089D0 (en) * 1989-08-18 1989-08-18 Novo Nordisk As PROTEINS
ATE135585T1 (en) * 1990-08-27 1996-04-15 Monsanto Co ANTICOAGULATORY COMPOSITION OF LACI AND SULFATED POLYSACCHARIDES
IL104325A (en) * 1992-01-07 2000-10-31 Novo Nordisk As Variants of human kunitz-type protease inhibitor domain II of tissue factor pathway inhibitor (TFPI) pharmaceutical compositions containing them a DNA construct encoding them their expression vectors a cell containing said DNA constructs and methods for the production of all the above
IL104326A0 (en) * 1992-01-07 1993-05-13 Novo Nordisk As Variant of human kunitz-type protease inhibitor
IL104324A0 (en) * 1992-01-07 1993-05-13 Novo Nordisk As Variant of human kunitz-type protease inhibitor
US5212091A (en) * 1992-03-02 1993-05-18 Monsanto Company Method of producing tissue factor pathway inhibitor
DE69528591T2 (en) * 1994-08-05 2003-02-20 Chiron Corp PRODUCTION OF THE INHIBITOR FOR THE COMPLEX FORMATION OF THE TISSUE FACTOR

Also Published As

Publication number Publication date
EP0774001A1 (en) 1997-05-21
JP3779728B2 (en) 2006-05-31
EP0774001B1 (en) 2002-10-16
DE69528591T2 (en) 2003-02-20
AU707762B2 (en) 1999-07-22
WO1996004377A1 (en) 1996-02-15
ATE226249T1 (en) 2002-11-15
CA2196296A1 (en) 1996-02-15
JP2005348744A (en) 2005-12-22
US20050064556A1 (en) 2005-03-24
US6103500A (en) 2000-08-15
JPH10507071A (en) 1998-07-14
CA2196296C (en) 2004-04-06
AU3104495A (en) 1996-03-04

Similar Documents

Publication Publication Date Title
ATE226249T1 (en) PRODUCTION OF THE INHIBITOR FOR THE COMPLEX FORMATION OF THE TISSUE FACTOR
CA2203936A1 (en) Boronic ester and acid compounds, synthesis and uses
MY132115A (en) Novel thrombin inhibitors
EP1352627A3 (en) Reduction of hair growth
WO1998051799A1 (en) Novel differentiation inhibitor
EP0206801A3 (en) Tissue-affinitive collagen for osteogenesis and method of producing the same
ATE218336T1 (en) USE OF 3-BENZOYLPHENYLACETIC ACIDS, THEIR ESTERS OR AMIDES FOR THE TREATMENT OF GLC1A GLAUCOMA
AU4312285A (en) Collagen and or fibrinogen as carrier of drugs for their introduction into cellular lesion areas
DE68923819T2 (en) Use of gamma-hydroxy butyric acid salts for the manufacture of pharmaceutical compositions for use in the treatment of alcoholism and the compositions prepared.
CA2160366A1 (en) Risperidone pamoate
EP0832203A4 (en) Use of neuro-derived fetal cell lines for transplantation therapy
CA2200480A1 (en) New use of prostaglandins
IT1275556B (en) PROCESS AND PLANT FOR THE DEHYDRATION OF FORAGE, IN PARTICULARLY FOR THE DEHYDRATION OF THE MEDICAL GRASS
CA2215303A1 (en) Sertoli cells as transplantation facilitator for cell transplantation
EP1002538A3 (en) Stem cell and lymphocyte storage
CA2216583A1 (en) Levobupivacaine and its use as an anaesthetic in pregnant women
UA41975C2 (en) method for the thermal treatment of alloy aluminium-lithium and method for formation of structure glued with adhesive
MX9801133A (en) Didepsipeptide-based endoparasiticides, new didepsipeptides and process for preparing the same.
TW336890B (en) Method of making more than one punchout from a single dried blood spot
AU2408395A (en) New peptide active substance and production thereof
CA2006845A1 (en) Expression of proteinaceous sweeteners in yeast
EP0371733A3 (en) Dopamine-beta-hydroxylase inhibitors
EP0661293A3 (en) Protein having cell growth-stimulating and macrophage chemotactic actions, preparative method therefor and use thereof
CA2105861A1 (en) Fish Production
IE780669L (en) Antihypertensive compositions

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: NOVARTIS VACCINES AND DIAGNOSTICS,INC.(N.D.GES, US

8339 Ceased/non-payment of the annual fee